AI
SLDB icon

ArchPoint Investors’s Solid Biosciences SLDB Stock Holding History

ArchPoint Investors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
+31,326
New +$237K 0.07% 67

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ArchPoint Investors's SLDB Position: Q2 2026 in Review

ArchPoint Investors opened a new position in Solid Biosciences (SLDB) in Q2 2026: 31,326 shares worth $313K. The stake represents 0.07% of the portfolio and ranks #67 among its holdings.

157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • ArchPoint Investors held 31,326 shares of Solid Biosciences worth $313K as of Q2 2026.
  • Solid Biosciences was a new ArchPoint Investors position in Q2 2026.
  • Solid Biosciences made up 0.07% of ArchPoint Investors's portfolio in Q2 2026, its #67 holding.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on ArchPoint Investors's 13F filing for Q2 2026, filed 13 Aug 2026.